How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Castration-Resistant Prostate Cancer Therapeutics Market
- By Therapeutic Class: Androgen Receptor Inhibitors, Chemotherapy Agents, Immunotherapy, Radiopharmaceuticals, Hormonal Therapy
- By Mechanism of Action: Androgen Biosynthesis Inhibitors, Androgen Receptor Antagonists, Cytotoxic Agents, Checkpoint Inhibitors, Radioligand Therapy
- By Route of Administration: Oral, Intravenous, Intramuscular, Subcutaneous
- By Line of Therapy: First-line Treatment, Second-line Treatment, Third-line and Beyond
- By Patient Population: Metastatic CRPC, Non-metastatic CRPC, Chemotherapy-Naive Patients, Post-Chemotherapy Patients
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Androgen Receptor Inhibitors leads By Therapeutic Class at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 17 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
12 chapters · 301 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.66 →
- 11 Competitive Landscape 5 sections p.179 →
- 12 Company Profiles 17 players: SWOT & benchmarking p.187 →
Full report · locked preview
Everything inside the Castration-Resistant Prostate Cancer Therapeutics Market report
A complete, evidence-based study - 12 chapters and 126 sections covering market size, segmentation across 5 axes, regional analysis and 17 company profiles, forecast to 2033.
Segmentation covered
Therapeutic Class 5
Mechanism of Action 5
Route of Administration 4
Line of Therapy 3
Patient Population 4
Companies profiled
Johnson & Johnson (Janssen Pharmaceuticals)
Astellas Pharma Inc.
Pfizer Inc.
Bayer AG
Sanofi S.A.
Novartis International AG
Amgen Inc.
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
Daiichi Sankyo Company
Limited
Ipsen S.A.
+5 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
17 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Johnson & Johnson (Janssen Pharmaceuticals)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Astellas Pharma Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Pfizer Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Bayer AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Sanofi S.A.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Novartis International AG
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Amgen Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.191 →Bristol-Myers Squibb Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →F. Hoffmann-La Roche AG
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Daiichi Sankyo Company
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Limited
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Ipsen S.A.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Exelixis Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.227 →Menarini Group
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Eli Lilly and Company
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →Seattle Genetics
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.245 →Inc.
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.250 →Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Global · 2025–2033
$944.2M by 2033 · 7.9% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Androgen Receptor Inhibitors52.8
- Chemotherapy Agents10.1
- Immunotherapy12.8
- Radiopharmaceuticals8.1
- Hormonal Therapy16.3
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$169.2M → $343.9M · 9.3%
Europe$117.9M → $233.0M · 8.9%
Asia Pacific$107.7M → $191.0M · 7.4%
Latin America$66.7M → $126.1M · 8.3%
Middle East and Africa$51.3M → $100.8M · 8.8%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →7.882026
7.902027
7.912028
7.912029
7.932030
7.952031
7.952032
7.972033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Johnson & Johnson (Janssen Pharmaceuticals)27.4
- Astellas Pharma Inc.11.6
- Pfizer Inc.5.3
- Bayer AG11.6
- Sanofi S.A.6.2
- Novartis International AG10.0
- Others27.9
Segment contribution to growth (%)
Fig. 18 · p.39 →Therapeutic Class19.6%
Mechanism of Action10.7%
Route of Administration24.6%
Line of Therapy25.0%
Patient Population20.1%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America34.6
- Europe23.4
- Asia Pacific19.2
- Latin America12.7
- Middle East and Africa10.1
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Johnson & Johnson (Janssen Pharmaceuticals) | 76 | 77 | 94 | 94 | 92 | 92 | 88 |
| Astellas Pharma Inc. | 81 | 90 | 77 | 88 | 84 | 83 | 84 |
| Pfizer Inc. | 69 | 71 | 73 | 83 | 79 | 62 | 73 |
| Bayer AG | 80 | 61 | 81 | 60 | 69 | 59 | 68 |
| Sanofi S.A. | 72 | 73 | 56 | 68 | 76 | 57 | 67 |
| Novartis International AG | 52 | 58 | 65 | 68 | 71 | 46 | 60 |
| Amgen Inc. | 56 | 65 | 49 | 56 | 41 | 62 | 55 |
| Bristol-Myers Squibb Company | 53 | 54 | 52 | 40 | 42 | 42 | 47 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Johnson & Johnson (Janssen Pharmaceuticals)
- Astellas Pharma Inc.
- Pfizer Inc.
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Johnson & Johnson (Janssen Pharmaceuticals) | ◐ | ◐ | ◐ | ✓ | ✓ | ✓ |
| Astellas Pharma Inc. | ✓ | ✓ | ✓ | ✓ | ◐ | ◐ |
| Pfizer Inc. | − | ◐ | ◐ | ✓ | ◐ | − |
| Bayer AG | ◐ | ◐ | ✓ | ◐ | ◐ | ◐ |
| Sanofi S.A. | ✓ | ✓ | ◐ | − | ◐ | − |
| Novartis International AG | − | − | ◐ | ◐ | ◐ | − |
| Amgen Inc. | − | ◐ | − | − | − | ◐ |
| Bristol-Myers Squibb Company | ◐ | ◐ | ◐ | − | − | − |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Johnson & Johnson (Janssen Pharmaceuticals)88
2Astellas Pharma Inc.84
3Pfizer Inc.73
4Bayer AG68
5Sanofi S.A.67
6Novartis International AG60
7Amgen Inc.55
8Bristol-Myers Squibb Company47
Competitive tiers
§8.4 · p.172 →Leader2
Set the pace on share, breadth and innovation.
Johnson & Johnson (Janssen Pharmaceuticals)Astellas Pharma Inc.
Challenger3
Strong scale, closing on the leaders.
Pfizer Inc.Bayer AGSanofi S.A.
Contender1
Focused players with pockets of strength.
Novartis International AG
Niche2
Specialists in a single segment or region.
Amgen Inc.Bristol-Myers Squibb Company
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Go-to-market strategy
Land Therapeutic Class in North America, then scale across Castration-Resistant Prostate Cancer Therapeutics Market — a $50M beachhead inside a $915M market.
Beachhead (SOM)$50Mobtainable near-term
Serviceable (SAM)$315Mreachable market
Primary motionPartner-led + digitalgo-to-market
Time to scale4 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion89 fit
Androgen Receptor Inhibitors
Best fit — highest urgency & budget in Therapeutic Class.
Economic buyer76 fit
Chemotherapy Agents
Strong fit — clear ROI and a fast path to value.
End user64 fit
Immunotherapy
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Therapeutic Class in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Mechanism of Action & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + Route of Administration
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales43%
Partner / channel27%
Digital / self-serve21%
Marketplaces9%
Positioning & messaging
§GTM 2 · p.194 →For Therapeutic Class leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Castration-Resistant Prostate Cancer Therapeutics Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified42%
Sales qualified24%
Evaluation14%
Closed-won8%
$19.9KCAC
$74KLTV
3.7:1LTV : CAC
< 2 moCAC payback
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Investment thesis
Castration-Resistant Prostate Cancer Therapeutics Market is a durable-growth opportunity — $5.74B by 2033, compounding at 6.8%.
TAM · 2025$3.39Btoday
TAM · 2033$5.74Bforecast
CAGR6.8%2027–2033
Cumulative$40.3Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.74BTotal addressable market
SAM$2.23BServiceable available market
SOM$362MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →6.8% CAGR
Demand compounds through 2033, outpacing GDP across Therapeutic Class.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Therapeutic Class moving from early to mainstream — durable secular demand.
Consolidation upside
17+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.74BLarge & growingTAM by 2033 at 6.8% CAGR
$2.23BServiceable nowreachable with today’s model
$362MBeachhead winobtainable near-term share
17+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.48BBear4.4% CAGR
$5.74BBase6.8% CAGR
$7.35BBull9.0% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Mechanism of Action optionality
- Customer concentrationBroaden installed base beyond top accounts
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Board pack · executive summary
Castration-Resistant Prostate Cancer Therapeutics Market — a $3.39B market by 2033. Plan: grow share from 7.1% to 11.6%.
Market size · 2033$3.39Btotal addressable
Market CAGR3.2%2027–2033
Target share11.6%from 7.1% today
Revenue ambition$393Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 7.1% | 11.6% | Behind |
| Revenue | $244M | $393M | Ahead |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 3 of 5 axes | 5 of 5 axes | Ahead |
| Gross margin | 33.2% | 44.0% | On track |
| Customer retention | 91.4% | 93.7% | Behind |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Therapeutic Class
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Mechanism of Action capability
A defensible second engine — invest in Mechanism of Action to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Therapeutic Class share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Mechanism of Action
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $41M capacity & capability investment
- Greenlight bolt-on M&A in Mechanism of Action
- Authorise North America expansion plan
- Fund R&D program for Therapeutic Class leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownBehind
- Competitive share lossOn track
- Input-cost & supply riskAt risk
- Regulatory / policy changeOn track
- Execution & talentOn track
Values shown here are illustrative samples for your understanding — not exact figures. The full report contains the real, verified data.
Sales deck · value proposition
Win the Castration-Resistant Prostate Cancer Therapeutics Market conversation — a $11.0B market you can size, segment and defend in minutes.
Market size · 2033$11.0Btotal opportunity
Growth10.2%CAGR to 2033
Addressable buyers1,442+accounts in scope
Typical ROI6.3×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Therapeutic Class
Goal Grow share in Therapeutic Class
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.3×return on cost, year one
< 3 mopayback period
$66K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
17+players profiled in this market
Coverage includes
Johnson & Johnson (Janssen Pharmaceuticals)Astellas Pharma Inc.Pfizer Inc.Bayer AGSanofi S.A.Novartis International AGAmgen Inc.Bristol-Myers Squibb Company+9 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Castration-Resistant Prostate Cancer Therapeutics Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Castration-Resistant Prostate Cancer Therapeutics Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Cast-Resin Bus Duct Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportCasual Dining Market
Market size, share, segmentation and regional forecast.
$1.6B market · 2025 base year
View reportCasual Dining Restaurant Chains Market
Market size, share, segmentation and regional forecast.
$926M market · 2025 base year
View reportCasual Sandal Market
Market size, share, segmentation and regional forecast.
$1.7B market · 2025 base year
View reportCasual Sneaker Market
Market size, share, segmentation and regional forecast.
$3.7B market · 2025 base year
View reportCasualty Treaty Reinsurance Market
Market size, share, segmentation and regional forecast.
$398M market · 2025 base year
View reportCat And Dog Hair Dryer Market
Market size, share, segmentation and regional forecast.
$680M market · 2025 base year
View reportCat bed Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportCat Cage Market
Market size, share, segmentation and regional forecast.
$6.2B market · 2025 base year
View reportCat Chewing Sticks Market
Market size, share, segmentation and regional forecast.
$2.2B market · 2025 base year
View reportCat Collar Market
Market size, share, segmentation and regional forecast.
$2.4B market · 2025 base year
View reportCat Collars Market
Market size, share, segmentation and regional forecast.
$2.9B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report is readable online in full. Downloadable formats are available as optional $99 add-ons: a formatted PDF and a fully editable XLSX containing all underlying data tables - so you can re-chart, re-model, or drop any figure straight into your own deck.